The U.S. ​Food and Drug ‌Administration on Wednesday approved Eli Lilly's weight-loss pill, making ​it the second ​to market after Novo Nordisk's ⁠oral Wegovy, as ​the companies fight to ​capture more customers with the convenience of pills over injectables.